CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Celldex Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$29.67+2.14 (+7.77%)
Close on Oct 19, 2026
- Market cap
- $2.31B
- P/E (TTM)
- –
- Dividend yield
- –
Celldex Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contracts and grants | $15.00K | $15.00K | $81.00K | $0 | $723.00K | $645.00K | $1.17M | $3.19M | $2.50M | $154.00K | $3.87M | $1.52M | 68.2% | -97.9% |
| Product development and licensing agreements | $7.00K | – | $40.00K | $0 | $7.00K | $50.00K | $8.00K | $3.00K | $0 | $2.00K | $259.00K | $2.00K | 31.8% | 0.0% |
By region
From the segment and revenue-disaggregation notes of Celldex Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.